Diagnosis of latent polycythemia vera: A clinician’s opinion

Abstract

Chronic myeloproliferative disease that is characterized by the JAK2 V617F mutation, borderline hemoglobin counts, and morphological features of a bone marrow trephine biopsy specimen, which are specific for PV, is an independent PV variant, namely: latent PV.

Cerebrovascular Disorders Associated with Ph-Negative Myeloproliferative Diseases

“…В прогностической шкале IPSET-thrombosis при ЭТ мутация V617F в гене JAK2 включена как прогностический фактор риска развития тромботических осложнений. Однако число наблюдений среди наших пациентов с ЭТ (JAK2+) недостаточно для проведения статистического анализа [17][18][19].…”

Miyeloproliferatif Hastalıkların Tanısının Moleküler Genetik Yönü: Polisitemi Vera Örneği

“…Myeloproliferative disorders (MDs) are a group of clonal disorders of the hematopoietic stem cells and are characterized by the neoplastic proliferation of one or more lineages of myelopoiesis, with a change in peripheral blood indices (1,2). They can be classified according to the presence of the Philadelphia chromosome.…”

“…They can be classified according to the presence of the Philadelphia chromosome. Philadelphia-positive MDs include chronic myeloid leukemia (CML), which is driven by the Philadelphia chromosome, while polycythemia vera (PV), myelofibrosis, and essential thrombocythemia, which are not associated with the Philadelphia chromosome, are called Philadelphia-negative MDs (2,3). MDs also include a nonclassifiable group, which is referred to as "unclassified myeloproliferative disorders".…”

“…Almost all patients with PV are carriers of a janus kinase 2 (JAK2) V617F mutation or another functionally similar mutation. PV is a rare (orphan) disease with annual prevalence of 0.4 to 2.8 cases per 100,000 population and typically presents in late adulthood, although it has also been reported in younger patients, with a female predominance (1,2).…”